Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955123 | 0.85 | HPGD (0.50) | MAPTHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27650744 | 0.85 | ALOX15 (0.59) | MAOBAOC3MAPTHPGDSMN1; SMN2 | |
| SCHEMBL3373804 | 0.81 | HPGD (0.47) | MAPTHPGDSMN1; SMN2LMNAKDM4E | |
| SCHEMBL24352748 | 0.81 | MAOB (0.50) | MAOBAOC3MAPTHPGDSMN1; SMN2 | |
| SCHEMBL19249734 | 0.80 | HPGD (0.46) | MAPTHPGDSMN1; SMN2LMNAKDM4E | |
| SCHEMBL11178901 | 0.80 | ALOX15 (0.53) | MAOBAOC3MAPTHPGDSMN1; SMN2 | |
| SCHEMBL14265184 | 0.80 | RAB9A (0.44) | MAPTHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17285623 | 0.79 | ALDH1A1 (0.64) | MAPTHPGDSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL28492011 | 0.79 | NPSR1 (0.62) | MAOBAOC3MAPTHPGDSMN1; SMN2 | |
| SCHEMBL28501266 | 0.79 | ALDH1A1 (0.58) | MAOBAOC3MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656347-B1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7709521-B2 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1656347-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | Astrazeneca AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019171-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | IDO1, IDO2, TPH1 | MAOB 41/4885AOC3 2443/4885MAPT 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.